Attached files
| file | filename |
|---|---|
| EX-10.16 - EX-10.16 - CRISPR Therapeutics AG | d183927dex1016.htm |
| EX-21.1 - EX-21.1 - CRISPR Therapeutics AG | d183927dex211.htm |
| EX-10.17 - EX-10.17 - CRISPR Therapeutics AG | d183927dex1017.htm |
| EX-10.15 - EX-10.15 - CRISPR Therapeutics AG | d183927dex1015.htm |
| EX-10.14 - EX-10.14 - CRISPR Therapeutics AG | d183927dex1014.htm |
| EX-10.9 - EX-10.9 - CRISPR Therapeutics AG | d183927dex109.htm |
| EX-4.1 - EX-4.1 - CRISPR Therapeutics AG | d183927dex41.htm |
| EX-3.1 - EX-3.1 - CRISPR Therapeutics AG | d183927dex31.htm |
| S-1 - S-1 - CRISPR Therapeutics AG | d183927ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated May 13, 2016 (except note 17, as to which the date is July 26, 2016) in the Registration Statement (Form S-1) and the related Prospectus of CRISPR Therapeutics AG dated September 9, 2016.
/s/ Ernst & Young LLP
Boston, Massachusetts
September 9, 2016